Loading
Pelabresib is an experimental small-molecule drug from Novartis Pharmaceuticals in phase 3 trials, with its target not yet stated publicly.
Pelabresib (CPI-0610) is a small-molecule drug developed by Novartis Pharmaceuticals. The sponsor describes its target as BET (bromodomain and extraterminal protein), which OnCo does not yet have a target page for. The sponsor states: A small-molecule BET protein inhibitor. ClinicalTrials.gov describes the intervention as: Small molecule inhibitor of bromodomain and extraterminal (BET) protein. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib). The largest, NCT06401356, plans to enrol 50 participants with primary completion expected 2027-06-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A small-molecule BET protein inhibitor. Connects to BRD4.
1.Pelabresib slips into a pocket on BRD4.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pelabresib" OR ABSTRACT:"Pelabresib" OR TITLE:"CPI-0610" OR ABSTRACT:"CPI-0610") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pelabresib, not a curated reading list.
Shares Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Novartis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.
Shares Primary myelofibrosis and the tag pipeline.